Table 2.

 Six month outcomes in patients stratified by CYP3A4 metabolised statin use

Outcome	All patients with acute coronary syndromes
	No clopidogrel + no statin (n = 331)	Clopidogrel + no statin (n = 180)	Clopidogrel + CYP3A4 (n = 561)	Clopidogrel + non-CYP3A4 (n = 91)	p Value*
Death	57 (17.2%)	18 (10%)	32 (5.7%)	3 (3.3%)	0.24
MI	14 (8.3%)	10 (8.9%)	28 (7.6%)	9 (9.7%)	0.39
Stroke	3 (1.1%)	2 (1.3%)	5 (1.4%)	0 (0%)	0.70
MACE	73 (22.1%)	30 (16.7%)	64 (11.4%)	12 (13.2%)	0.54

*Comparisons between patients who received CYP3A4 statin versus a non-CYP3A4 statin with clopidogrel.

MACE, major adverse cardiac outcomes (composite of death, MI, and stroke).